Ariel, Israel: Cannabis inhalation is associated with symptom relief and improved quality of life in subjects with hyperemesis gravidarum (HG), according to a summary of four case reports published in the Journal of Cannabis Research.
A pair of researchers affiliated with Ariel University and Shamir Hospital in Israel evaluated the use of cannabis in four women with HG. The subjects were evaluated both before and following their use of cannabis.
All four subjects experienced “highly significant improvements” in their symptoms, including relief from nausea and vomiting, as well as a reversal of weight loss. Cannabis inhalation was also associated with a “significant increase” in subjects’ quality of life scores. Authors reported that the maternal use of cannabis did not appear to adversely impact either pre-natal or post-natal development, though they cautioned that “no formal testing” was performed post-child birth.
Investigators concluded, “While more research is needed before cannabis can be considered for use in HG, this report suggests that cannabis should be tested in appropriately-powered control trials for this severe and protracted maternal condition, addressing both maternal effect and potential adverse fetal effects.”
Full text of the study, “The use of cannabis for hyperemesis gravidarum,” appears in the Journal of Cannabis Research.